


Supplementary Table 1. Baseline characteristics of patients according to treatment option

	<i>Change to RAI/surgery N = 192</i>	<i>ATD treatment N = 1,235</i>	<i>P</i>
Age (years)	33.7 (26.9–47.2)	45.9 (35.2–55.0)	< 0.001
Sex, male	64 (33.3%)	385 (31.2%)	0.606
Smoking			< 0.001
Non-smoker	168 (87.5%)	1,172 (94.9%)	
Ex-smoker	10 (5.2%)	24 (1.9%)	
Current smoker	14 (7.3%)	39 (3.2%)	
Goiter ^a			< 0.001
Grade 0	41 (21.4%)	556 (45.0%)	
Grade 1	58 (30.2%)	534 (43.2%)	
Grade 2	93 (48.4%)	145 (11.7%)	
TAO			0.625
Absence	163 (84.9%)	1,073 (86.9%)	
Mild	15 (7.8%)	78 (6.3%)	
Moderate to Severe	14 (7.3%)	84 (6.8%)	
Initial Free T4 (ng/dL)	2.7 (1.9–4.1)	2.5 (2.0–3.4)	0.084
Initial TRAb (IU/L)	24.9 (9.5–40.0)	8.9 (4.7–17.5)	< 0.001

Continuous variables are presented as median (interquartile range) and categorical variables as numbers (percentages). ^aWHO goiter classification system, grade 0: no goiter; grade 1: thyroid palpable but not visible; grade 2: thyroid visible with the neck in normal position

TAO, thyroid-associated ophthalmopathy; ATD, antithyroid drug; TSH, thyroid stimulating hormone; TRAb, thyrotropin receptor antibody

Supplementary Figure 1. Pattern of thyrotropin receptor antibody trend



TRAb, thyrotropin receptor antibody